- Conditions
- Lymphoma
- Interventions
- epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 162
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab
- Biological · Procedure · Radiation
- Lead sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 4
- States / cities
- Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab, Placebo
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more
- Conditions
- Leukemia
- Interventions
- epratuzumab, clofarabine, cytarabine, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years to 120 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 81
- States / cities
- Little Rock, Arkansas • Duarte, California • Los Angeles, California + 57 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- New York, New York • Pittsburgh, Pennsylvania • Charleston, South Carolina
- Conditions
- Leukemia, Pediatric Cancer
- Interventions
- Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- epratuzumab, rituximab
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 43
- States / cities
- San Diego, California • San Francisco, California • Middletown, Connecticut + 33 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 44 more
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 31 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- hLL2 (epratuzumab)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- epratuzumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma
- Interventions
- Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 7
- States / cities
- Newark, Delaware • Orlando, Florida • Tampa, Florida + 4 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 63 more
- Conditions
- Lymphoma
- Interventions
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Procedure · Radiation
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 120 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Clearwater, Florida • Baltimore, Maryland + 1 more
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Epratuzumab (hLL2- anti-CD22 humanized antibody)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
- Conditions
- Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Cutaneous Lymphoma, Lymphomas: Non-Hodgkin Diffuse Large B-Cell, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell, Lymphomas: Non-Hodgkin Mantle Cell, Lymphomas: Non-Hodgkin Marginal Zone, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
- Interventions
- Rituximab, Epratuzumab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lymphoma
- Interventions
- epratuzumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- hLL2 (Epratuzumab)
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Lymphoma
- Interventions
- indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
- Radiation
- Lead sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 2
- States / cities
- Belleville, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Follicular Lymphoma
- Interventions
- 90Y-epratuzumab tetraxetan, veltuzumab
- Drug · Biological
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York